The 5th Leading International Cancer Immunotherapy Conference In Europe

Starts On: 19/03/2018
Ends At: 21/03/2018
Country: Germany
City: Berlin
Contact Email:
Contact Phone: +43 1 405 13 83 18
Conference Website
1 Star2 Stars3 Stars4 Stars5 Stars (3 votes, average: 5.00 out of 5)



Welcome Message

The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) has the great pleasure to invite you to take part in the 5th Immunotherapy of Cancer Conference (ITOC5) – the leading International conference in Europe providing a global platform for translational research in the field of immuno-oncology.

The ITOC series of conferences is the premier meeting for education, scientific exchange, and networking within the cancer immunotherapy field.

It aims at providing a forum for all professionals working in immunotherapy to discuss early clinical drug development and address the unique challenges of translational research.

The programme will focus on the latest challenges and innovations with a special emphasis on combination therapy, immuno-monitoring and biomarker development.

At this conference, we are in particular addressing preclinical and clinical scientists, clinical investigators, postdoctoral fellows involved in cancer research, regulatory scientists, healthcare professionals and the pharmaceutical industry

Join us in Berlin, Germany on 19 – 21 March 2018 to help push further the opportunities that will ultimately aid in revolutionizing the way cancer is treated.

Help us promote the conference with the Congress Flyer!
Print it out and pin it to your notice board!

Important dates

Registration opens September 1, 2017
Abstract submission opens September 1, 2017
Abstract submission closes December 1, 2017
Early rate registration closes December 15, 2017
Regular rate registration closes March 9, 2018
ITOC5 Conference March 19 – 21, 2018
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *